Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey A Block

Showing results (111-120 of 117) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 117 results.
American Journal of Nephrology|March 31, 2021
Study Design and Baseline Characteristics of the CARDINAL Trial: A Phase 3 Study of Bardoxolone Methyl in Patients with Alport SyndromeGlenn M Chertow, Gerald B Appel, Sharon Andreoli, et al.
American Heart Journal|November 1, 2020
Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: Design and baseline characteristicsGlenn M Chertow, Pablo E Pergola, Rajiv Agarwal, et al.
The New England Journal of Medicine|April 9, 2004
Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysisGeoffrey A Block, Kevin J Martin, Angel L M de Francisco, et al.
Clinical Journal of the American Society of Nephrology : CJASN|November 21, 2022
Effects of Bardoxolone Methyl in Alport SyndromeBradley A Warady, Pablo E Pergola, Rajiv Agarwal, et al.
The New England Journal of Medicine|April 29, 2021
Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing DialysisKai-Uwe Eckardt, Rajiv Agarwal, Ahmad Aswad, et al.
The New England Journal of Medicine|April 29, 2021
Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKDGlenn M Chertow, Pablo E Pergola, Youssef M K Farag, et al.
Journal of the American Society of Nephrology : JASN|September 12, 2020
A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD)Nigel D Toussaint, Eugenia Pedagogos, Nicole M Lioufas, et al.
Pageof 12

Showing results (111-120 of 117) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 117 results.
American Journal of Nephrology|March 31, 2021
Study Design and Baseline Characteristics of the CARDINAL Trial: A Phase 3 Study of Bardoxolone Methyl in Patients with Alport SyndromeGlenn M Chertow, Gerald B Appel, Sharon Andreoli, et al.
American Heart Journal|November 1, 2020
Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: Design and baseline characteristicsGlenn M Chertow, Pablo E Pergola, Rajiv Agarwal, et al.
The New England Journal of Medicine|April 9, 2004
Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysisGeoffrey A Block, Kevin J Martin, Angel L M de Francisco, et al.
Clinical Journal of the American Society of Nephrology : CJASN|November 21, 2022
Effects of Bardoxolone Methyl in Alport SyndromeBradley A Warady, Pablo E Pergola, Rajiv Agarwal, et al.
The New England Journal of Medicine|April 29, 2021
Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing DialysisKai-Uwe Eckardt, Rajiv Agarwal, Ahmad Aswad, et al.
The New England Journal of Medicine|April 29, 2021
Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKDGlenn M Chertow, Pablo E Pergola, Youssef M K Farag, et al.
Journal of the American Society of Nephrology : JASN|September 12, 2020
A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD)Nigel D Toussaint, Eugenia Pedagogos, Nicole M Lioufas, et al.
Pageof 12